IL10RA and neoplasm: In the present work we demonstrated for the first time that the application of cellular vaccines based on DCs with downregulated IL-10R expression preceded by the administration of HES-MTX nanoconjugate – the chemotherapeutic with immunomodulatory potential, resulted in the creation of an efficient and specific anti-tumor immune response leading to significant inhibition of tumor growth.